BeiGene, Ltd. (BGNE): Price and Financial Metrics


BeiGene, Ltd. (BGNE): $305.54

-2.27 (-0.74%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BGNE Stock Summary

  • BGNE has a market capitalization of $28,015,967,661 -- more than approximately 91.12% of US stocks.
  • With a price/sales ratio of 90.7, BeiGene Ltd has a higher such ratio than 96.21% of stocks in our set.
  • With a year-over-year growth in debt of 102.63%, BeiGene Ltd's debt growth rate surpasses 89.79% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to BeiGene Ltd are WDC, ZLAB, SRPT, XLRN, and EDIT.
  • BGNE's SEC filings can be seen here. And to visit BeiGene Ltd's official web site, go to www.beigene.com.

BGNE Stock Price Chart Interactive Chart >

Price chart for BGNE

BGNE Price/Volume Stats

Current price $305.54 52-week high $388.97
Prev. close $307.81 52-week low $136.48
Day low $302.04 Volume 168,100
Day high $308.14 Avg. volume 307,063
50-day MA $331.11 Dividend yield N/A
200-day MA $281.59 Market Cap 28.02B

BeiGene, Ltd. (BGNE) Company Bio


BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People’s Republic of China. The company was founded in 2010 and is based in the Cayman Islands.


BGNE Latest News Stream


Event/Time News Detail
Loading, please wait...

BGNE Latest Social Stream


Loading social stream, please wait...

View Full BGNE Social Stream

Latest BGNE News From Around the Web

Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.

BeiGene's tislelizumab combo study shows antitumor activity in solid tumors

BeiGene (BGNE) presents clinical data on tislelizumab, in combination with sitravatinib being jointly developed with Mirati Therapeutics (MRTX) at the American Association for Cancer Research ((AACR)) Annual Meeting 2021.Data presented were from two cohorts of Phase 1b trial in patients with unresectable or metastatic melanoma who were refractory or resistant to...

Seeking Alpha | April 12, 2021

BeiGene Reports Phase 1b Data For Sitravatinib And Tislelizumab Combination

L1 resistant or refractory melanoma.

Kailas Salunkhe on TipRanks | April 12, 2021

BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced results from a planned interim analysis of the Phase 3 RATIONALE 303 trial of its anti-PD-1 antibody tislelizumab compared to docetaxel as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021. A supplemental biologics application (sBLA) based on these results from the RATIONALE 303 trial was accepted in March 2021 and is currently under regulatory review in China.

Yahoo | April 12, 2021

BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics, Inc. (Mirati), were presented in two oral presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial (NCT03666143), in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer (PROC).

Yahoo | April 11, 2021

BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study

BeiGene Ltd (NASDAQ: BGNE ) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental … Full story available on Benzinga.com

Benzinga | April 8, 2021

Read More 'BGNE' Stories Here

BGNE Price Returns

1-mo -6.23%
3-mo -11.44%
6-mo 1.33%
1-year 94.08%
3-year 80.65%
5-year 883.39%
YTD 18.25%
2020 55.88%
2019 18.18%
2018 43.53%
2017 221.87%
2016 N/A

Continue Researching BGNE

Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:

BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0231 seconds.